Sickle cell
FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
Actualités
janvier 8, 2020
FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
Global Blood Therapeutics, Inc. announced only a few hours ago that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta™ (previously known as Voxelotor) tablets…
Hypertension Medication Valsartan May Help Prevent Vaso-Occlusive Episodes in Sickle Cell Disease
Actualités
septembre 19, 2019
Hypertension Medication Valsartan May Help Prevent Vaso-Occlusive Episodes in Sickle Cell Disease
A medication used to treat high blood pressure, called Valsartan, may help decrease the stickiness of red blood cells and reduce the risk of vaso-occlusive crisis in people with sickle cell…